I need to read through this filing carefully. The filing is a Form 10-Q for DiaMedica Therapeutics Inc. for the quarterly period ended June 30, 2026. Let me identify the substantive disclosure content beyond boilerplate to check the word count gate - the filing text provided is largely cover page, table of contents, and the cautionary forward-looking statements section. The actual financial data, MD&A results, and other substantive disclosures appear to be cut off. However, the forward-looking statements section does contain substantive content about the company's clinical programs, trial status, and operational details that exceed 150 words. The ticker from the cover page registered-securities table is DMAC on The Nasdaq Stock Market LLC.

DiaMedica Therapeutics Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 10, 2026, covering the quarterly period ended June 30, 2026.

Key Highlights

  • Share count: As of August 3, 2026, there were 53,925,697 voting common shares outstanding, according to the filing.
  • Exchange listing: The company's voting common shares trade on The Nasdaq Stock Market LLC under the symbol DMAC.
  • ReMEDy2 trial challenges: The filing cites slower than expected site activations and enrollment in the Phase 2/3 ReMEDy2 trial for acute ischemic stroke, attributing this in part to hospital and medical facility staffing shortages.
  • ReMEDy2 trial design: The trial is intended to enroll approximately 300 patients at up to 100 sites globally, with a possible final sample size of up to 728 patients based on an interim analysis of 200 participants, per a pre-determined statistical plan.
  • Mitigation actions: The company disclosed actions to address enrollment challenges, including expanding its internal clinical team, bringing certain trial activities in-house, globally expanding the trial, and making certain changes to the study protocol.
  • Filer status: DiaMedica is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page.

DiaMedica's Q2 2026 Report: Clinical Trial Progress and Enrollment Challenges

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), incorporated in British Columbia, Canada, with principal executive offices at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, submitted its Form 10-Q for the quarterly period ended June 30, 2026. The company's sole product candidate, DM199, is being studied for the treatment of preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), according to the filing.

The filing describes the Phase 2/3 ReMEDy2 clinical trial of DM199 for AIS as facing headwinds. According to the company's disclosure, slower than expected site activations and enrollment are believed to be due, in part, to hospital and medical facility staffing shortages, inclusion and exclusion criteria in the study protocol, concerns about managing logistics and protocol compliance for participants discharged to intermediate care facilities, and concerns regarding prior clinically significant hypotension events and circumstances surrounding a clinical hold that was lifted in June 2023. The filing also notes that the use of artificial intelligence and telemedicine has enabled smaller hospitals to retain AIS patients who are not eligible for mechanical thrombectomy, reducing the pool of patients available at larger stroke centers that are more likely to serve as trial sites.

In response to these challenges, the company disclosed several mitigation actions, including significantly expanding its internal clinical team, bringing in-house activities such as study site identification, qualification and activation, clinical site monitoring, supporting vendor management, and overall program management, as well as globally expanding the trial and making certain changes to the study protocol. The filing also references an ongoing Phase 2, proof-of-concept investigator-sponsored clinical trial of DM199 for PE and FGR being conducted by physician collaborators. The company disclosed plans to seek U.S. Food and Drug Administration approval for a clinical study of DM199 for PE and FGR. The filing notes uncertainties relating to regulatory applications in light of recent changes in funding and staffing levels at the FDA and other government agencies. Forward-looking statements in this report are the company's own and are subject to its cautionary language as described in the filing.

What Was Disclosed

DiaMedica Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, reporting 53,925,697 common shares outstanding as of August 3, 2026, and disclosing ongoing clinical trial activities and enrollment challenges for its DM199 product candidate.